News

Missoula’s Inimmune receives $600K to develop novel treatments for seasonal allergies

Missoula-based Inimmune Corp. has received a nearly $600,000 federal grant to identify and advance novel treatments for seasonal allergies. In an announcement Wednesday, the biotechnology firm said the two-year project will be led by Dr. Juhienah Khalaf, a medicine...
Read More

Inimmune named one of the top 8 Montana startups to watch

Originally written by DAVID ERICKSON (david.erickson@missoulian.com) and reported in the Missoulian.    Three Missoula companies and two others in western Montana have made the Montana High Tech Business Alliance’s list of “Startups to Watch” in 2018 due to their...
Read More

Montana company receives funds for cutting edge infectious disease research and novel immunotherapeutic treatments

Inimmune Corporation, a startup biotechnology company located in Missoula Montana, recently received a Phase I Small Business Innovation Research (SBIR) award in the amount of $176,000 from the National Institute for Allergy and Infectious Diseases (NIAID). The...
Read More

Inimmune lands Montana Department of Commerce Grant to Fund Technology Innovation

Montana Department of Commerce Director Pam Haxby-Cote today announced $862,000 in grants to nine research projects in five communities to encourage innovation, research and high-wage job creation.

Read More

Upcoming Events
Look for us at these upcoming conferences. If you are interested in scheduling a face to face meeting during one of these conferences please use the contact button.

ACS- August 2016

NIH Workshop on waning immunity and microbial vaccines – September 19, 2016 (Rockville, MD)

AAPS- November 2016

PEG- 2016, Boston

Experimental Biology- April 2017

ASPET- April 2017

AAI- May 2017

Relevant Publications

Smith AJ, Li Y, Bazin-Lee H, St-Jean JR, Larocque D, Baldridge J. Evaluation of novel synthetic TLR7/8 agonists as human vaccine adjuvants. Vaccine. 2016. [Epub ahead of print].

Oberoi, H.; Yorgensen, Y.; Evans, J.; Burkhart, D.; PEG modified liposomes in combination with methylglycol chitosan enhances the murine sublingual immune response to influenza vaccination  Journal of Controlled Release, Vol 223, 10 Feb 2016.

Spinner, J.; Oberoi, H.; Yorgensen, Y.; Burkhart, D.; Evans, J.;  Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually  Vaccine, Volume 33, pages5845-5853, 2015.

Khalaf, W. S. Bowen, H.G. Bazin , K.T. Ryter, M.T. Livesay, J.R. Ward, J.T. Evans, D.A. Johnson, “Characterization of TRIF selectivity in the AGP class of lipid A mimetics: Role of secondary lipid chains”, Bioorg. Med. Chem. Lett., 25, 547-533, 2015

H.G. Bazin, Y. Li, J.K. Khalaf , S. Mwakwari, M.T. Livesay, J.T. Evans, D.A. Johnson, “Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives”,  Bioorg. Med. Chem. Lett., 25, 1318-1323, 2015

H.G. Bazin, L.S. Bess, M.T. Livesay, D.A. Johnson, “Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method”, Tetrahedron Lett, 57, 2063-2066, 2016

Mwakwari, L.S. Bess, H.G. Bazin, D.A. Johnson, “Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline”, Tetrahedron Lett, 57, 2093-2096, 2016

 

Copyright © 2015 Inimmune